{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:48:03Z","timestamp":1793321283417,"version":"4.5.0"},"reference-count":33,"publisher":"Centers for Disease Control MMWR Office","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6703a5","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T12:59:24Z","timestamp":1516885164000},"page":"103-108","source":"Crossref","is-referenced-by-count":562,"title":["Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines"],"prefix":"10.15585","volume":"67","author":[{"given":"Kathleen L.","family":"Dooling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Harpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2018,1,26]]},"reference":[{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R1","unstructured":"Food and Drug Administration. Shingrix [package insert]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581605.pdf"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database.","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R5","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1742-1241.2009.02089.x","article-title":"Postherpetic neuralgia in the elderly.","volume":"63","author":"Johnson","year":"2009","journal-title":"Int J Clin Pract"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R6","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R7","first-page":"1528","article-title":"Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R8","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine.","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R9","unstructured":"CDC. Obtaining and evaluating evidence with grading of recommendations, assessment, development and evaluation (GRADE) for herpes zoster vaccines. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy.","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years.","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R13","unstructured":"Prosser LA. Economic evaluation of vaccination for prevention of herpes zoster and related complications [slides]. Presentation to the Advisory Committee on Immunization Practices; October 25, 2017; Atlanta, Georgia. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-10\/zoster-03-prosser.pdf"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R14","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older.","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R16","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/infdis\/jiw046","article-title":"Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine.","volume":"213","author":"Chesson","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2337\/dc12-0759","article-title":"Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes.","volume":"36","author":"Hoerger","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R18","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the Adjuvanted herpes zoster subunit vaccine in older adults.","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R19","unstructured":"Leidner AJ. Overview of two economic models that assess the cost-effectiveness of herpes zoster vaccinations [slides]. Presentation to the Advisory Committee on Immunization Practices; June 21, 2017; Atlanta, Georgia. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-06\/zoster-04-leidner.pdf"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R20","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1093\/ofid\/ofx163.1039","article-title":"Persistence of immune response to an adjuvanted varicella\u2010zoster virus subunit candidate vaccine for up to year 9 in older adults.","volume":"4","author":"Pauksens","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R21","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1093\/ofid\/ofx163.1038","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in older adults previously vaccinated with a live-attenuated herpes zoster vaccine: a phase III, group-matched, clinical trial.","volume":"4","author":"Grupping","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R22","unstructured":"Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE): recombinant zoster vaccine (RZV) and herpes zoster live-attenuated vaccine (ZVL). Atlanta, GA: US Department of Health and Human Services, CDC, Advisory Committee on Immunization Practices; 2017. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/herpes-zoster.html"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older.","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study.","volume":"187","author":"Baxter","year":"2017","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R25","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years.","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ofid\/ofw194.41","article-title":"Effectiveness of live zoster vaccine in preventing postherpetic neuralgia (PHN).","volume":"3","author":"Baxter","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R27","unstructured":"Food and Drug Administration. Zostavax [package insert]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM132831.pdf"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R28","doi-asserted-by":"publisher","first-page":"bcr2015212688","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R29","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10\u202fyear review of post-marketing safety experience.","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study.","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R31","unstructured":"Kroger AT, Duchin J, V\u00e1zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R32","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6703a5-201801260856-R33","unstructured":"Colindres R. Safety summary of investigational vaccine: Shingrix. [slides]. Presentation to the Advisory Committee on Immunization Practices; February 22, 2017; Atlanta, Georgia.\n                      \n                      https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-02\/zoster-02-gsk.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T08:58:55Z","timestamp":1516957135000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6703a5.htm?s_cid=mm6703a5_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,26]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,1,26]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6703a5","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,26]]},"published":{"date-parts":[[2018,1,26]]}}}